医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Takeda to Present at the 34th Annual J.P. Morgan Healthcare Conference

2016年01月08日 AM10:00
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

Takeda Pharmaceutical Company Limited (TOKYO: 4502) (“Takeda”) today announced that Christophe Weber, President and Chief Executive Officer of Takeda, will make a formal presentation on January 12, local time, at the 34th Annual J.P. Morgan Healthcare Conference held in San Francisco, California. The presentation will be followed by a Q&A session.

Details of the timing, and how to access the audio webcast and presentation materials, are as follows.

Date and
time

  Tuesday January 12, at 11:30am – 12:30pm (Pacific Standard Time)

[Wednesday January 13, at 4:30am – 5:30am (Japan Standard Time)]

Agenda

Presentation (25 minutes): Takeda Strategic Update
Christophe Weber, President and Chief Executive Officer

(Note: Includes updates on ENTYVIO® sales from Oct-Dec 2015, and Takeda’s direction in R&D)

 

 

Q&A session (25 minutes)

Christophe Weber, President and Chief Executive Officer

Andrew Plump, Chief Medical & Scientific Officer

Rudolf van Houten, acting Chief Financial Officer

Christophe Bianchi, President, Global Oncology Business Unit

Access to
audio
webcast

 

http://bit.ly/1TH6bTS

Registration is required in advance, so please visit the URL a few minutes before the presentation is scheduled to begin.

In addition to a live webcast, the audio will also be available on-demand at this URL for 90 days following the event.

Access to
presentation
materials

 

Presentation materials will be uploaded to Takeda’s website at the same time as the presentation begins:
http://bit.ly/1O6KRFX

Note: Audio and materials are available only in English.

 

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda (TOKYO: 4502) is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.takeda.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006438/en/

CONTACT

Media Contacts:
Takeda Pharmaceutical Company Limited
Tsuyoshi
Tada, +81 3-3278-2417
tsuyoshi.tada@takeda.com
Investor
Contacts:

Takeda Pharmaceutical Company Limited
Noriko
Higuchi, +81 3-3278-2306
noriko.higuchi@takeda.com

同じカテゴリーの記事 

  • C2N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing for Alzheimer’s Disease and Brain Research Market
  • BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report
  • Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China